Atelocollagen-mediated systemic DDS for nucleic acid medicines

被引:32
作者
Hanai, Koji
Takeshita, Fumitaka
Honma, Kimi
Nagahara, Shunji
Maeda, Miho
Minakuchi, Yoshiko
Sano, Akihiko
Ochiya, Takahiro
机构
[1] Dainippon Sumitomo Pharma Co Ltd, Formulat Labs, Technol Res & Dev Ctr, Osaka 5670878, Japan
[2] Natl Canc Ctr, Inst Res, Tokyo 1040045, Japan
[3] Koken Biosci Inst, Tokyo 1150051, Japan
来源
OLIGONUCLEOTIDE THERAPEUTICS | 2006年 / 1082卷
关键词
atelocollagen; drug delivery system; oligonucleotides; siRNA; antisense; systemic treatment;
D O I
10.1196/annals.1348.010
中图分类号
O [数理科学和化学]; P [天文学、地球科学]; Q [生物科学]; N [自然科学总论];
学科分类号
07 [理学]; 0710 [生物学]; 09 [农学];
摘要
The goal of our research is to provide a practical platform for drug delivery in oligonucleotide therapy. We report here the efficacy of an atelocollagen-mediated oligonucleotide delivery system applied to systemic siRNA and antisense oligonucleotide treatments in animal disease models. Atelocollagen and oligonucleotides formed a complex of nanosized particles, which was highly stable against nucleases. The complex allowed oligonucleotides to be delivered efficiently into several organs and tissues via intravenous administration. In a tumor metastasis model, the complex successfully delivered siRNA to metastasized tumors in bone tissue and inhibited their growth. We also demonstrated that a single intravenous treatment of the antisense oligodeoxynucleotide complex suppressed ear dermatitis in a contact hypersensitivity model. These results indicate the strong potential of the atelocollagen-mediated drug delivery system for practical therapeutic technology.
引用
收藏
页码:9 / 17
页数:9
相关论文
共 14 条
[1]
Potential of atelocollagen-mediated systemic antisense therapeutics for inflammatory disease [J].
Hanai, K ;
Kurokawa, T ;
Minakuchi, Y ;
Maeda, M ;
Nagahara, S ;
Miyata, T ;
Ochiya, T ;
Sano, A .
HUMAN GENE THERAPY, 2004, 15 (03) :263-272
[2]
Antisense oligodeoxynucteotide against HST-1/FGF-4 suppresses tumorigenicity of an orthotopic model for human germ celt tumor in nude mice [J].
Hirai, K ;
Sasaki, H ;
Sakamoto, H ;
Takeshita, F ;
Asano, K ;
Kubota, Y ;
Ochiya, T ;
Terada, M .
JOURNAL OF GENE MEDICINE, 2003, 5 (11) :951-957
[3]
Atelocollagen-based gene transfer in cells allows high-throughput screening of gene functions [J].
Honma, K ;
Ochiya, T ;
Nagahara, S ;
Sano, A ;
Yamamoto, H ;
Hirai, K ;
Aso, Y ;
Terada, M .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2001, 289 (05) :1075-1081
[4]
In vivo monitoring of tumor relapse and metastasis using bioluminescent PC-3M-luc-C6 cells in murine models of human prostate cancer [J].
Jenkins, DE ;
Yu, SF ;
Hornig, YS ;
Purchio, T ;
Contag, PR .
CLINICAL & EXPERIMENTAL METASTASIS, 2003, 20 (08) :745-756
[5]
Klimuk SK, 2000, J PHARMACOL EXP THER, V292, P480
[6]
Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo -: art. no. e109 [J].
Minakuchi, Y ;
Takeshita, F ;
Kosaka, N ;
Sasaki, H ;
Yamamoto, Y ;
Kouno, M ;
Honma, K ;
Nagahara, S ;
Hanai, K ;
Sano, A ;
Kato, T ;
Terada, M ;
Ochiya, T .
NUCLEIC ACIDS RESEARCH, 2004, 32 (13) :e109
[7]
MIYATA T, 1992, Clinical Materials, V9, P139, DOI 10.1016/0267-6605(92)90093-9
[8]
New delivery system for plasmid DNA in vivo using atelocollagen as a carrier material:: the Minipellet [J].
Ochiya, T ;
Takahama, Y ;
Nagahara, S ;
Sumita, Y ;
Hisada, A ;
Itoh, H ;
Nagai, Y ;
Terada, M .
NATURE MEDICINE, 1999, 5 (06) :707-710
[9]
Ochiya Takahiro, 2001, Current Gene Therapy, V1, P31, DOI 10.2174/1566523013348887
[10]
Atelocollagen for protein and gene delivery [J].
Sano, A ;
Maeda, M ;
Nagahara, S ;
Ochiya, T ;
Honma, K ;
Itoh, H ;
Miyata, T ;
Fujioka, K .
ADVANCED DRUG DELIVERY REVIEWS, 2003, 55 (12) :1651-1677